Rachel Layman

Clinical trials

• Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

  Principal investigator · Terminated · Phase 1, Phase 2

  National Cancer Institute (NCI)

  2022–2023
• Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

  Principal investigator · Terminated · Phase 1, Phase 2

  M.D. Anderson Cancer Center

  2022–2024
• Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

  Principal investigator · Terminated · Phase 1, Phase 2

  M.D. Anderson Cancer Center

  2018–2025
• Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

  Principal investigator · Completed

  Ohio State University Comprehensive Cancer Center

  2011